|
rs56350726
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Correction: A genetic variant in SLC28A3, rs56350726, is associated with progression to castration-resistant prostate cancer in a Korean population with metastatic prostate cancer.
|
30159135 |
2018 |
|
rs56350726
|
|
|
0.020 |
GeneticVariation |
BEFREE |
And one (SLC28A3, rs56350726) of five SNP was found the association with the progression to CRPC in patients with mPCa.
|
29228579 |
2017 |
|
rs976306779
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Hence, S100P could be considered a potential drug target or a chemosensitization target, and could also serve as a biomarker for aggressive, hormone-refractory and metastatic prostate cancer.
|
18452169 |
2008 |
|
rs976306779
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Interleukin-6 is a potent inducer of S100P, which is up-regulated in androgen-refractory and metastatic prostate cancer.
|
15474988 |
2005 |
|
rs1870050
|
|
|
0.010 |
GeneticVariation |
BEFREE |
These findings suggest that genetic variation in CYP19A1 (rs1870050) might affect the prognosis of patients with metastatic prostate cancer when treated with ADT by regulating serum testosterone levels.
|
30868236 |
2019 |
|
rs6259
|
|
|
0.010 |
GeneticVariation |
BEFREE |
This study suggested genetic variation in SHBG (rs6259) might be an independent prognostic biomarker among men treated with primary ADT for metastatic prostate cancer.
|
31036465 |
2019 |
|
rs544190
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The association of prostate cancer antigen 3 (PCA3) polymorphism (SNP, rs544190G>A) with metastatic prostate cancer in European descent has been reported.
|
29412547 |
2018 |
|
rs12030724
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Moreover, polymorphism (rs12030724) in the YB-1 gene affected YB-1 expression in 93 prostate cancer tissues (YB-1 positive rate; 14.3% in TT, 40.0% in AT, and 52.9% in AA, P = .04) and associated with probability of progression in 104 metastatic prostate cancer case patients (AT/TT vs AA, hazard ratio = 0.49, 95% confidence interval = 0.32 to 0.77, P = .001).
|
26857528 |
2016 |
|
rs2208532
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We studied the polymorphisms rs518673 and rs166050 in SRD5A1, and rs12470143, rs523349, rs676033 and rs2208532 in SRD5A2 as well as the time to CRPC progression and overall survival in 104 patients with metastatic prostate cancer that had undergone primary ADT.
|
26169017 |
2015 |
|
rs523349
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Furthermore, SRD5A2 rs523349 polymorphism may be a promising biomarker for metastatic prostate cancer patients treated with primary ADT and a molecular target for advanced prostate cancer.
|
26169017 |
2015 |
|
rs676033
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We studied the polymorphisms rs518673 and rs166050 in SRD5A1, and rs12470143, rs523349, rs676033 and rs2208532 in SRD5A2 as well as the time to CRPC progression and overall survival in 104 patients with metastatic prostate cancer that had undergone primary ADT.
|
26169017 |
2015 |
|
rs10993994
|
|
|
0.010 |
GeneticVariation |
BEFREE |
MSMB rs10993994 (per variant allele summary RR = 1.24, 95% CI = 1.05-1.48), 8q24 rs4242382 (RR = 1.40, 95% CI = 1.13-1.75), and 8q24 rs6983267 (RR = 0.67, 95% CI = 0.50-0.89) were associated with risk for metastatic prostate cancer.
|
21343373 |
2011 |
|
rs28934578
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Twist1 levels were also elevated in metastatic prostate cancer-derived cell line DU145, in immortalized lung fibroblasts and in a subset of lung cancer samples, all in a mutant p53-dependent manner. p53(R175H) mutant bearing immortalized epithelial cells showed typical features of EMT, such as higher expression of mesenchymal markers, lower expression of epithelial markers and enhanced invasive properties in vitro.
|
20689556 |
2011 |
|
rs4242382
|
|
|
0.010 |
GeneticVariation |
BEFREE |
MSMB rs10993994 (per variant allele summary RR = 1.24, 95% CI = 1.05-1.48), 8q24 rs4242382 (RR = 1.40, 95% CI = 1.13-1.75), and 8q24 rs6983267 (RR = 0.67, 95% CI = 0.50-0.89) were associated with risk for metastatic prostate cancer.
|
21343373 |
2011 |
|
rs6983267
|
|
|
0.010 |
GeneticVariation |
BEFREE |
MSMB rs10993994 (per variant allele summary RR = 1.24, 95% CI = 1.05-1.48), 8q24 rs4242382 (RR = 1.40, 95% CI = 1.13-1.75), and 8q24 rs6983267 (RR = 0.67, 95% CI = 0.50-0.89) were associated with risk for metastatic prostate cancer.
|
21343373 |
2011 |
|
rs2011077
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Regarding the rs2011077 polymorphism, individuals with the GG genotype had a 6.260- and 3.033-fold increased risk of prostate cancer and BPH, and a 5.550-fold increased risk of metastatic prostate cancer compared with those with the AA genotype.
|
18756523 |
2008 |
|
rs1374051619
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We examined polymorphisms within ELAC2 (S217L, A541T, E622V), MSR1 (P275A, R293X, aIVS5-59c), and RNASEL (E265X, R462Q, D541E) in 150 European-Americans with metastatic prostate cancer and 170 prostate cancer-free controls using pyrosequencing assays.
|
16114055 |
2006 |
|
rs41341748
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We examined polymorphisms within ELAC2 (S217L, A541T, E622V), MSR1 (P275A, R293X, aIVS5-59c), and RNASEL (E265X, R462Q, D541E) in 150 European-Americans with metastatic prostate cancer and 170 prostate cancer-free controls using pyrosequencing assays.
|
16114055 |
2006 |
|
rs627928
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We examined polymorphisms within ELAC2 (S217L, A541T, E622V), MSR1 (P275A, R293X, aIVS5-59c), and RNASEL (E265X, R462Q, D541E) in 150 European-Americans with metastatic prostate cancer and 170 prostate cancer-free controls using pyrosequencing assays.
|
16114055 |
2006 |
|
rs765521022
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Interleukin-6 is a potent inducer of S100P, which is up-regulated in androgen-refractory and metastatic prostate cancer.
|
15474988 |
2005 |